MedPath

Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer

Not Applicable
Completed
Conditions
Early-Stage Breast Carcinoma
Interventions
Procedure: without preoperative access to lymphoscintigraphy findings
Registration Number
NCT02481128
Lead Sponsor
Kliniken Essen-Mitte
Brief Summary

Sentinel node biopsy is a well established tool for axillary staging in early breast cancer. So far the impact of a preoperative lymph node scintigraphy is unclear. This study aims to clarify whether a preoperative lymphoscintigraphy is of additional benefit in a prospective randomized multicenter study design.

Detailed Description

Sentinel node biopsy is a well established tool for axillary staging in early breast cancer. So far the impact of a preoperative lymph node scintigraphy is unclear. Several studies indicate sentinel node biopsy to be a reliable method irrespective of prior lymph node scintigraphy, but data from prospective randomized trials are not available.

Although a preoperative lymph node scintigraphy is not explicitly demanded in current S3 guidelines in Germany its performance is a common practice.

If a preoperative lymphoscintigraphy could be safely omitted, possible benefits are a facilitation of the preoperative workflow as well as cost reduction for health care systems.

This study aims to clarify whether a preoperative lymphoscintigraphy is of additional benefit in a prospective randomized study design. In the two study arms sentinel node biopsy is performed either with or without knowledge of the preoperative lymphoscintigraphy findings. Primary end point is the average number of histologically detected sentinel lymph nodes per patient in both treatment arms.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1198
Inclusion Criteria
  • invasive mamma carcinoma as verified by core cut biopsy
  • extensive ductal carcinoma in situ as verified by core cut biopsy (at least 5 cm or at least 2,5 cm and G3 grading)
  • clinical stage tumor T1-T3
  • no signs of axillary lymph node metastasis on clinical examination including ultrasound examination
  • no signs of distant metastatic disease
  • male/ female patient in the age not less than 18 years
  • Karnofsky performance status at least 70% or Eastern Cooperative Oncology Group (ECOG) score not higher than 1
  • written patient informed consent
Exclusion Criteria
  • suspect axillary lymph nodes on clinical/ultrasound examination
  • positive fine-needle biopsy of axillary lymph nodes
  • sentinel lymph node biopsy to be performed after neoadjuvant chemotherapy
  • recurrence of a mamma carcinoma
  • prior extensive surgery of breast or axilla
  • inflammatory or extramammary breast cancer
  • pregnancy
  • contraindication to the radionuclide
  • inability to understand the studies purpose
  • inability to receive surgery
  • no written patient informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
B (no access to lymphoscintigraphy)without preoperative access to lymphoscintigraphy findingsAxillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
Primary Outcome Measures
NameTimeMethod
Average number of histologically detected sentinel lymph nodes per patientHistological report expected within an average of 2 weeks after sentinel lymph node biopsy

Number of resected sentinel lymph nodes is inversely correlated with false negative rate of sentinel lymph node biopsy. Average number of histologically detected sentinel lymph nodes per patient is assessed through pathologic report and serves as surrogate marker for false negative rate of sentinel node biopsy.

Secondary Outcome Measures
NameTimeMethod
Rate of patients with proven metastasis in sentinel lymph nodesHistological report expected within an average of 2 weeks after sentinel lymph node biopsy
Rate of completion axillary dissection with proven metastasis in sentinel lymph nodeshistological report on subsequent completion axillary dissection within 6 months after initial sentinel lymph node biopsy

A completion axillary dissection can be performed in case of proven metastasis in sentinel lymph nodes. A completion axillary dissection ca be performed either right away during sentinel lymph node biopsy or after completion of neoadjuvant chemotherapy. Hence assessment will be performed within 6 months after initial sentinel lymph node biopsy in order to include all patients planned for neoadjuvant chemotherapy.

Detection rates of sentinel nodes lymph nodes with preoperative lymphoscintigraphy vs. intraoperative gamma probe and histological detection rates of sentinel lymph nodes with vs. without preoperative access to lymphoscintigraphyHistological report expected within an average of 2 weeks after sentinel lymph node biopsy

Trial Locations

Locations (23)

Klinikum Gütersloh, Klinik für Frauenheilkunde und Geburtshilfe

🇩🇪

Gütersloh, Germany

Sankt Elisabeth Krankenhaus Gütersloh, Frauenklinik

🇩🇪

Gütersloh, Germany

Kreisklinik Ebersberg, Brustzentrum

🇩🇪

Ebersberg, Germany

Kliniken Essen-Mitte

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Brustzentrum am Hochwaldkrankenhaus Bad Nauheim

🇩🇪

Bad Nauheim, Germany

Brustzentrum im Klinikum Ansbach

🇩🇪

Ansbach, Germany

Franziskus Hospital Harderberg, Brustzentrum Osnabrück

🇩🇪

Georgsmarienhütte, Germany

Asklepios Harzkliniken Goslar, Brustzentrum

🇩🇪

Goslar, Germany

Klinik für Frauenheilkunde & Geburtshilfe, Klinikum Esslingen

🇩🇪

Esslingen, Germany

Agaplesion Markus Krankenhaus Frankfurt, Brustzentrum

🇩🇪

Frankfurt a. M., Germany

Universitätsklinikum Hamburg Eppendorf

🇩🇪

Hamburg, Germany

Kreiskrankenhaus Bergstrasse, Brustzentrum

🇩🇪

Heppenheim, Germany

Universitätsklinikum Schleswig-Holstein, Brustzentrum Kiel

🇩🇪

Kiel, Germany

Universitätsfrauenklinik am Klinikum Südstadt Rostock

🇩🇪

Rostock, Germany

Universitätsfrauenklinik Magdeburg, Brustzentrum

🇩🇪

Magdeburg, Germany

Evangelisches Krankenhaus Bethesda, Brustzentrum Niederrhein

🇩🇪

Mönchengladbach, Germany

DRK Krankenhaus Saarlouis, Brustzentrum

🇩🇪

Saarlouis, Germany

Marien-Hospital Wesel, Brustzentrum

🇩🇪

Wesel, Germany

Klinikum St. Elisabeth Straubing, Brustzentrum

🇩🇪

Straubing, Germany

Leopoldina Krankenhaus Schweinfurt, Brustzentrum

🇩🇪

Schweinfurt, Germany

Katharinen Hospital Unna, Brustzentrum

🇩🇪

Unna, Germany

Kliniken Nordoberpfalz, Frauenklinik

🇩🇪

Weiden, Germany

Brustzentrum Bern, Engerriedspital/Lindenhofspital

🇨🇭

Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath